Last reviewed · How we verify
3mg Liraglutide for Overweight or Obesity
In this study investigators will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and body composition), biochemical parameters, metabolomics and micro-ribonucleotide acid (miRNA) molecules from blood tests. Liraglutide is a commercially available analogue of a gut hormone physiologically produced in our bowel in response to food, licenced for the treatment of overweight or obesity. Liraglutide will be offered to patients attending National Health System (NHS) or private clinics within indication and according to their agreed clinical management. Investigators aim to collect real-life information for this study along with planned clinical management from patients who agree to their treatment and to take part in our study. Patients will be able to withdraw from treatment and study at any time without giving any explanation. If successful, this study will help us combine clinical, biochemical and molecular information which will allow us to gain deeper understanding on the mechanisms behind the beneficial metabolic effects of Liraglutide in overweight and obesity. Data generated from this study will hopefully help us acquire funding for a larger multicentre study; the results of which can have substantial impact on millions of people with overweight or obesity around the world.
Details
| Lead sponsor | University Hospitals Coventry and Warwickshire NHS Trust |
|---|---|
| Status | COMPLETED |
| Enrolment | 43 |
| Start date | Fri Jan 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Overweight
- Obesity
- Infertility, Female
Interventions
- Saxenda
- Lifestyle modification
- Metabolomics
- miRNA
Countries
United Kingdom